Overview

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Status:
Recruiting
Trial end date:
2025-06-15
Target enrollment:
Participant gender:
Summary
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent [68Ga]Ga-PTF) , versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.
Phase:
Phase 3
Details
Lead Sponsor:
Pentixapharm AG
Collaborator:
Pivotal S.L.
Treatments:
Fluorodeoxyglucose F18